Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas

通过合作进行治愈：利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤

• 批准号: 10566833
• 负责人: DEBORAH STEPHENS
• 金额: $ 8.38万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-06 至 2023-08-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10566833
• 关键词: Adult; Advisory Committees; Advocate; Award; B-Cell Lymphomas; Caring; Catchment Area; Chronic Lymphocytic Leukemia; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Community Health Education; Community Outreach; Dedications; Development; Early Therapeutic-Clinical Trials Network; Fellowship; Funding; Grant; Hematological Disease; Hematology; Hematopoietic Neoplasms; Industry; International; Kentucky; Lead; Leadership; Longterm Follow-up; Lymphoma; Malignant Neoplasms; Mantle Cell Lymphoma; Mentorship; National Cancer Institute; Ohio; Outcome; Patient Care; Patients; Phase I/II Clinical Trial; Physicians; Principal Investigator; Protocols documentation; Publishing; Refractory; Relapse; Research; Research Institute; Research Personnel; Research Scientist Award; Review Committee; Role; Scientist; Small-Cell Lymphoma; Southwest Oncology Group; Specialist; Therapeutic; Time; Translations; Underrepresented Minority; Universities; Woman; Work; clinical investigation; fighting; improved; investigator-initiated trial; leukemia; leukemia/lymphoma; meetings; member; patient navigation; professor; programs; recruit; standard of care; therapy resistant; working group

PROJECT SUMMARY/ABSTRACT Deborah Stephens, DO is an Assistant Professor (to be Associate in July 2022) at the Huntsman Cancer Institute (HCI) who focuses on clinical investigation for patients with chronic lymphocytic leukemia (CLL) and B- cell lymphoma, the most common adult blood cancers. Despite recent advances in the field, CLL and relapsed/refractory B-cell lymphomas are mostly considered incurable. Resistance to therapy is common resulting in poor clinical outcomes. Dr. Stephens’s research is focused on CLL and lymphoma patient care and survival through development and management of a clinical trial portfolio at HCI that includes National Cancer Institute (NCI)-sponsored investigator-initiated trials. The scope of this program is significant, improves the care of local patients and has produced has changed the standard of care for patients internationally. Through several national and local leadership roles, Dr. Stephens dedicates 40% of her time to performing and promoting NCI-sponsored clinical trials. This work, currently not funded, would be supported by the R50 Research Scientist award and support the continuation and development of Dr. Stephens’s work. She is the CLL Lead for the SWOG Leukemia Working Group, which encompasses her roles as the national principal investigator (PI) for the S1925 EVOLVE CLL trial (NCT04269902) and leader of a task force to develop the next SWOG trial for CLL patients. Through the SWOG Lymphoma Working Group, Dr. Stephens has analyzed and published (as first author) the long-term follow-up of several pivotal lymphoma studies. She serves as the local PI for numerous NCI-sponsored CLL and lymphoma studies, which has resulting in placing HCI among leaders in national accrual in several studies including S1925, EA9161, and A041702 (CLL) and EA4151 and EA4181 (mantle cell lymphoma). At HCI, she serves on several committees dedicated to hematology clinical research, including HCI Hematology Disease Center (Interim Director), Hematology Clinical Trials Research Group (Physician Leader), Independent Protocol Review Committee (member), and the Center for Investigational Therapeutics (member). Building upon connections from her fellowship and extensive clinical trial collaboration with investigators at The Ohio State University (OSU), she developed a partnership with OSU and the University of Kentucky that enabled HCI’s successful UM1 ETCTN program application and resulted in grant 60075822 (Carson). She serves as the Hematology Expert for HCI on the ETCTN Executive Committee. The R50 Grant, would support Dr. Stephens to continue her work and plans for meeting the objectives of the NCI-funded clinical trials research program by (1) translation of HCI research into NCI-sponsored clinical trials and expand collaborative grant opportunities through advocating for targeted recruitment of key collaborating scientists, (2) expanding access to phase 1/2 clinical trials to all patients in HCI’s catchment areas, and (3) increasing the number of under-represented minorities and women through collaborations with HCI’s Community Outreach and Education and Patient Navigation Programs.

项目摘要/摘要 黛博拉·斯蒂芬斯（Deborah Stephens），do是亨斯曼癌症的助理教授（2022年7月成为助理） 研究所（HCI）专注于针对慢性淋巴细胞性白血病（CLL）和B-患者的临床投资 细胞淋巴瘤，最常见的成人血液癌。尽管该领域最近的进步，CLL和 复发/难治性B细胞淋巴瘤主要被认为是无法治愈的。对治疗的抵抗是常见的 导致临床结果不佳。斯蒂芬斯博士的研究侧重于CLL和淋巴瘤患者护理以及 通过在内的HCI的临床试验组合的开发和管理，包括国家癌 研究所（NCI）赞助的研究者发起的试验。该程序的范围很大，改善了 对当地患者的护理和生产的护理改变了国际患者的护理标准。 通过几个国家和地方领导职务，斯蒂芬斯博士将她的40％的时间献身于表演 并促进NCI赞助的临床试验。目前尚未资助的这项工作将得到R50的支持 研究科学家奖和支持Stephens博士工作的继续和发展。她是 CLL领导SWOG白血病工作组，该小组涵盖了她作为国家校长的角色 S1925 Evolve CLL试验（NCT04269902）的研究者（PI）和一个工作队的负责人 CLL患者的下一个swog试验。通过SWOG淋巴瘤工作组，Stephens博士分析了 并发表了（作为第一作者）的几项关键淋巴瘤研究的长期随访。她是 用于众多NCI赞助的CLL和淋巴瘤研究的局部PI，这导致HCI置于 在包括S1925，EA9161和A041702（CLL）和EA4151和EA4151和EA4151和EA4151和 EA4181（地幔细胞淋巴瘤）。在HCI，她在致力于血液学临床的多个委员会任职 研究，包括HCI血液学疾病中心（临时主任），血​​液学临床试验研究 小组（医师负责人），独立协议审查委员会（成员）和中心 研究治疗学（成员）。建立在她的团契和广泛临床的联系的基础上 她与俄亥俄州立大学（OSU）的研究人员合作，与OSU建立了合作伙伴关系 肯塔基大学启用了HCI成功的UM1 ETCTN计划申请，并导致了 授予60075822（卡森）。她是ETCTN执行委员会HCI的血液学专家。 R50赠款将支持Stephens博士继续她的工作，并计划实现 NCI资助的临床试验研究计划（1）将HCI研究转换为NCI赞助的临床 试验并扩大协作赠款机会，通过倡导目标招募关键 合作科学家，（2）扩大对HCI集水的所有患者的1/2阶段临床试验的访问 以及（3）通过与 HCI的社区外展和教育和患者导航计划。